https://www.selleckchem.com/products/gsk126.html
110 patients were randomised, 55 patients to tocilizumab (mean (SD) age 50.9 (12.4) years; women 98.2%) and 55 patients to placebo (54.8 (10.7) years; 90.9%). At 24 weeks, the proportion of patients meeting the primary endpoint was 52.7% (29/55) in the tocilizumab group and 63.6% (35/55) in the placebo group, for a difference of -11.4% (95% credible interval -30.6 to 9. (Pr[Toc Pla]=0.14). Among patients with primary Sjögren's syndrome, the use of tocilizumab did not improve systemic involvement and symptoms over 24 weeks of treatm
Like
Comment
Share
